CREATIVE MEDICAL TECHNOLOGY (CELZ) Stock Fundamental Analysis

NASDAQ:CELZ • US22529Y4089

1.945 USD
+0.01 (+0.26%)
At close: Feb 19, 2026
1.74 USD
-0.21 (-10.54%)
After Hours: 2/12/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall CELZ gets a fundamental rating of 3 out of 10. We evaluated CELZ against 521 industry peers in the Biotechnology industry. CELZ has a great financial health rating, but its profitability evaluates not so good. CELZ is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CELZ has reported negative net income.
  • In the past year CELZ has reported a negative cash flow from operations.
  • In the past 5 years CELZ reported 4 times negative net income.
  • CELZ had a negative operating cash flow in each of the past 5 years.
CELZ Yearly Net Income VS EBIT VS OCF VS FCFCELZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

  • CELZ's Return On Assets of -101.85% is on the low side compared to the rest of the industry. CELZ is outperformed by 75.62% of its industry peers.
  • CELZ has a Return On Equity (-106.61%) which is in line with its industry peers.
Industry RankSector Rank
ROA -101.85%
ROE -106.61%
ROIC N/A
ROA(3y)-61.52%
ROA(5y)-1011.99%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CELZ Yearly ROA, ROE, ROICCELZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K

1.3 Margins

  • CELZ's Gross Margin of 60.00% is fine compared to the rest of the industry. CELZ outperforms 78.50% of its industry peers.
  • CELZ's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for CELZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.52%
GM growth 5Y-3.2%
CELZ Yearly Profit, Operating, Gross MarginsCELZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20K -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • CELZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CELZ has been increased compared to 1 year ago.
  • The number of shares outstanding for CELZ has been increased compared to 5 years ago.
  • CELZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CELZ Yearly Shares OutstandingCELZ Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
CELZ Yearly Total Debt VS Total AssetsCELZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • CELZ has an Altman-Z score of -3.26. This is a bad value and indicates that CELZ is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of CELZ (-3.26) is comparable to the rest of the industry.
  • There is no outstanding debt for CELZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.26
ROIC/WACCN/A
WACC8.73%
CELZ Yearly LT Debt VS Equity VS FCFCELZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

2.3 Liquidity

  • A Current Ratio of 20.70 indicates that CELZ has no problem at all paying its short term obligations.
  • CELZ's Current ratio of 20.70 is amongst the best of the industry. CELZ outperforms 96.16% of its industry peers.
  • CELZ has a Quick Ratio of 20.70. This indicates that CELZ is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 20.70, CELZ belongs to the best of the industry, outperforming 96.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 20.7
Quick Ratio 20.7
CELZ Yearly Current Assets VS Current LiabilitesCELZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 23.02% over the past year.
  • The Revenue for CELZ has decreased by -45.45% in the past year. This is quite bad
  • The Revenue for CELZ have been decreasing by -42.17% on average. This is quite bad
EPS 1Y (TTM)23.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)-45.45%
Revenue growth 3Y-50.37%
Revenue growth 5Y-42.17%
Sales Q2Q%N/A

3.2 Future

  • CELZ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.08% yearly.
  • Based on estimates for the next years, CELZ will show a very strong growth in Revenue. The Revenue will grow by 535.57% on average per year.
EPS Next Y43.91%
EPS Next 2Y27.09%
EPS Next 3Y17.66%
EPS Next 5Y27.08%
Revenue Next Year-62.5%
Revenue Next 2Y-41.42%
Revenue Next 3Y1517.11%
Revenue Next 5Y535.57%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CELZ Yearly Revenue VS EstimatesCELZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
CELZ Yearly EPS VS EstimatesCELZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 40 60 80

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CELZ. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELZ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELZ Price Earnings VS Forward Price EarningsCELZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELZ Per share dataCELZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CELZ's earnings are expected to grow with 17.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.09%
EPS Next 3Y17.66%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CELZ!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CREATIVE MEDICAL TECHNOLOGY

NASDAQ:CELZ (2/19/2026, 4:30:00 PM)

After market: 1.74 -0.21 (-10.54%)

1.945

+0.01 (+0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)03-12
Inst Owners2.07%
Inst Owner Change48.87%
Ins Owners0.48%
Ins Owner Change0%
Market Cap6.79M
Revenue(TTM)6.00K
Net Income(TTM)-5.96M
Analysts82.86
Price Target20.4 (948.84%)
Short Float %9.61%
Short Ratio3.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.63%
Min EPS beat(2)1.96%
Max EPS beat(2)25.3%
EPS beat(4)2
Avg EPS beat(4)-25.88%
Min EPS beat(4)-74.29%
Max EPS beat(4)25.3%
EPS beat(8)4
Avg EPS beat(8)-10.63%
EPS beat(12)6
Avg EPS beat(12)-58.7%
EPS beat(16)7
Avg EPS beat(16)-149.2%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1131.34
P/FCF N/A
P/OCF N/A
P/B 1.21
P/tB 1.32
EV/EBITDA N/A
EPS(TTM)-2.91
EYN/A
EPS(NY)-1.43
Fwd EYN/A
FCF(TTM)-1.68
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS0
BVpS1.6
TBVpS1.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -101.85%
ROE -106.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60%
FCFM N/A
ROA(3y)-61.52%
ROA(5y)-1011.99%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.52%
GM growth 5Y-3.2%
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.7
Quick Ratio 20.7
Altman-Z -3.26
F-Score4
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
EPS Next Y43.91%
EPS Next 2Y27.09%
EPS Next 3Y17.66%
EPS Next 5Y27.08%
Revenue 1Y (TTM)-45.45%
Revenue growth 3Y-50.37%
Revenue growth 5Y-42.17%
Sales Q2Q%N/A
Revenue Next Year-62.5%
Revenue Next 2Y-41.42%
Revenue Next 3Y1517.11%
Revenue Next 5Y535.57%
EBIT growth 1Y-8.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.63%
OCF growth 3YN/A
OCF growth 5YN/A

CREATIVE MEDICAL TECHNOLOGY / CELZ FAQ

What is the ChartMill fundamental rating of CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CELZ.


Can you provide the valuation status for CREATIVE MEDICAL TECHNOLOGY?

ChartMill assigns a valuation rating of 0 / 10 to CREATIVE MEDICAL TECHNOLOGY (CELZ). This can be considered as Overvalued.


How profitable is CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?

CREATIVE MEDICAL TECHNOLOGY (CELZ) has a profitability rating of 1 / 10.


Can you provide the financial health for CELZ stock?

The financial health rating of CREATIVE MEDICAL TECHNOLOGY (CELZ) is 7 / 10.


What is the expected EPS growth for CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?

The Earnings per Share (EPS) of CREATIVE MEDICAL TECHNOLOGY (CELZ) is expected to grow by 43.91% in the next year.